Gaps in Post-Heart Attack Care Are Leaving Millions of Americans Unprotected

Heart attacks are survivable events for a growing share of Americans, but surviving one does not eliminate the risk of another. Secondary prevention — the systematic use of proven therapies after a myocardial infarction (MI) — is one of the most evidence-backed strategies in cardiovascular medicine. Yet real-world adherence tells a different story.

This study, published in the Journal of the American College of Cardiology by a Harvard-affiliated team including prominent cardiologist Peter Libby and Deepak Bhatt, examines the state of secondary prevention after MI across the United States. Using national data, the authors assess how well patients are receiving the guideline-recommended bundle of therapies designed to prevent recurrent events, including statins, antiplatelet agents, ACE inhibitors or ARBs, beta-blockers, and cardiac rehabilitation.

While the full dataset and results are not available from the abstract alone, the publication in a top-tier cardiology journal by a team of outcomes researchers signals a comprehensive, population-level analysis. The involvement of NIH/NHLBI funding and senior authors with deep expertise in cardiovascular outcomes research lends additional credibility to the work.

The implications are significant. Recurrent MIs are largely preventable, yet secondary prevention remains chronically underutilized — particularly among socioeconomically disadvantaged populations, women, and racial minorities. Identifying where these gaps exist is the essential first step toward closing them.

For clinicians, this paper serves as both a performance benchmark and a call to action — reinforcing that the work of a heart attack hospitalization does not end at discharge. For health systems, the findings likely underscore the need for structured follow-up protocols and quality improvement initiatives targeting post-MI care. A full reading of the manuscript is strongly recommended.